Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells
about
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidatesVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerUnderstanding and altering cell tropism of vesicular stomatitis virusChikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the BrainType III interferon attenuates a vesicular stomatitis virus-based vaccine vector.Current status of gene therapy for brain tumors.A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option.Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivoMutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsCurative one-shot systemic virotherapy in murine myeloma.RIG-I is required for VSV-induced cytokine production by murine glia and acts in combination with DAI to initiate responses to HSV-1.Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1.Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMAMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytesVesicular stomatitis virus as a treatment for colorectal cancerOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsA mathematical approach to virus therapy of glioblastomas.Visualizing infection spread: dual-color fluorescent reporting of virus-host interactions.Heterogeneous nuclear ribonucleoprotein K supports vesicular stomatitis virus replication by regulating cell survival and cellular gene expressionResistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapyVesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.Viral mutagenesis as a means for generating novel proteins.Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.VSV based virotherapy in ovarian cancer: the past, the present and …future?Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityPseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.Construction & establishment of two minigenome rescue systems for Chandipura virus driven by recombinant vaccinia virus expressing T7 polymerase.
P2860
Q27007519-19B38FA3-7C0C-4FD8-9DB9-193FB9ADB73BQ27021839-B5C46F4E-1F8A-4E25-B192-70764FECFD25Q27687067-C6870686-54ED-41F3-BCED-81875451E7B8Q28223031-0460E77D-8E69-40F4-8CE6-BEC583EB6A3AQ34262131-EE756A21-11AE-4D87-9B3E-3108A7DA6F32Q34318157-D9743214-D883-459D-B2C0-41D1E936B8BAQ34396290-1C0DAE88-13A6-43A4-BCCB-6B952C35C24DQ34656877-50FA2984-89DF-41A3-967F-0CE0DA4CEC0BQ35077031-179C3D50-66AF-4D71-A688-5D712AC7D2ABQ35077419-54A4C60F-C21C-497E-9EFC-7CAE85FA4C21Q35893563-A9A26F67-4364-472F-8BCC-CAE2D35C3716Q36139716-8133D63E-2079-416E-A4BB-438FE5D66088Q36145522-1A0899E3-5192-48EF-A8C9-AC8C2DC8FB02Q36172960-DA3D99E9-26EB-473B-97E3-77964B0C3581Q36202610-3503292C-C2D8-4074-B705-558599829744Q36549443-EC8C3185-139A-4121-B122-F93FEDD12611Q36751597-F1E0E6E1-F62F-4AB7-BF48-7A56E9A97849Q36911654-7DBE6ACC-33D5-4880-BADF-862F98C212CFQ36928614-29BFA95F-E9BD-42EF-B2C5-BDFBFF5BE8E5Q37123143-44313A8D-D21B-4C38-B3AB-1AC8738D3492Q37373616-CF73FC82-6119-4A68-8118-8DFA88CB540CQ37641644-EBF91FB1-5904-4365-898B-D03D79987ABBQ38286116-369C1512-B4BD-4D93-A842-72FBB034D23AQ38676507-27F59336-7B10-43D5-ADE3-B5B5057D3F04Q38860287-63DB9A6A-D084-4EDA-9AB9-80B23233ECA4Q38886667-F6FC7B96-196C-41FB-9043-D0CE441AEA49Q38923793-8B1EDF21-3EDF-4573-B19C-08DFCF52953EQ39063040-A7373DC2-B0D9-47C3-A25C-B81CE7BC6B34Q39127534-31A12B53-BA53-4515-B60D-718C58A106CFQ39224943-8D1D3CD3-6A1F-4324-A97D-95B01869D71DQ39354544-5C177D3B-908C-4FA9-827E-5881990BFEC7Q39404803-56A332B4-B054-45EA-B99F-7A7D61B08CE5Q39413447-3E5DB29E-43CC-405A-824D-487405E701D0Q39776023-156DA38F-1D47-48DE-AE5E-5AC4AB9635AEQ41379521-2770E8B5-702C-4026-820B-F8241BCF8BB8Q41441101-2BDDF4EB-6371-45DF-9376-905371402098Q41625843-990550C2-5D3E-4205-864C-22A5AF448712Q41770092-22BCA1E7-E4BF-486D-8B65-52D0D846B246Q41810186-E766D59D-19CB-4420-AC97-EF10E43A0F03Q41930117-87F435C4-F6C7-4623-B601-42B38DFB2D88
P2860
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Some attenuated variants of ve ...... relative to normal brain cells
@en
Some attenuated variants of ve ...... elative to normal brain cells.
@nl
type
label
Some attenuated variants of ve ...... relative to normal brain cells
@en
Some attenuated variants of ve ...... elative to normal brain cells.
@nl
prefLabel
Some attenuated variants of ve ...... relative to normal brain cells
@en
Some attenuated variants of ve ...... elative to normal brain cells.
@nl
P2093
P2860
P356
P1433
P1476
Some attenuated variants of ve ...... relative to normal brain cells
@en
P2093
Anthony N van den Pol
Guido Wollmann
John K Rose
Vitaliy Rogulin
P2860
P304
P356
10.1128/JVI.02040-09
P407
P577
2009-11-11T00:00:00Z